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Remotely Delivered Contraception With Needle-less
Norgestomet Implants
Darrel J. Kesler

Abstract: A remotely delivered contraceptive was
developed that suppressed estrus and prevented pregnancy
in deer with 100-percent efficacy. This contraceptive utilized
norgestomet, a potent progestin that is approved by the
Food and Drug Administration (FDA) for use in cattle.
Although the needle-less norgestomet implant is not FDA
approved for use in deer, it is safe for treated animals,
humans, and the environment. The remote delivery of this
implant can be accomplished up to 40 m away and causes
minimal tissue damage and stress if administered properly.
Because of its ease, its simplicity of delivery, and the control
it provides for proper drug handling, the needle-less
norgestomet implant holds much promise for control of the

overpopulation of deer in the United States. Further, no part
of this product will remain to pollute the environment.
Although this contraceptive was developed for female deer,
preliminary studies suggest that the needle-less norgestomet
implant may be effective in males. Widespread use of the
needle-less norgestomet implant in deer requires further
extensive (and costly) establishment of safety and efficacy
as well as FDA approval.
Kevwords: Remote deliverv, needle-less imDlants,
norgestomet, norethindroneacetate, wildlife contraception,
black-tailed deer, white-tailed deer, controlled release,
silicone, Food and Drug Administration

Introduction
Deer overpopulation has become a major problem in
many areas of the United States. Warren (1991) has
presented a detailed review of the historical causes of
this problem, the ecological effects of deer OverPoPulation, and the need for controlling deer populations.
Overpopulated deer herds are causing significant
economic losses in the form of crop damage, damage
to landscape plantings, transmission of diseases to
livestock such as cattle (Forbes and Tessaro 1993),
and damage to vehicles and humans (injury or death)
in deer-vehicle collisions. In many areas, regulated
~ u b l i chuntina has been Droven to be an effective
means of controlling deer populations (Behrend et al.
1970); however, this procedure has become very
controversial and political. Contraception of deer may,
therefore, be a logical alternative to control deer
.population.
.

Cost. The product has to be cost effective relative to
other methods of population control.

.

Efficacy, The product has to be highly effective,
~ l t h o u g h~oo-percentefficacy is not essential, like an
equivalent product for humans, it still must be highly
effective in reve en ti no
,. unwanted ~reanancies.
, "
Ease of delivery. The product must be uncomplicated and easy to deliver. Even if a product meets the
previous three criteria with 100-percent efficacy, it will
not be routinely used unless it can be delivered with
simplicity and ease.
~

~~~

~

u

The purpose of this article is not to provide an
extensive review of the literature but rather to review a
specific contraceptive (and its development) developed for deer. Because this contraceptive utilizes a
steroidal compound, I will refer to other steroids that
have been tested for deer contraception, but I will not
attempt to provide an extensive review of other
contraceptive compounds or procedures.
The selection of a deer contraceptive involves
several criteria. The following is a selected list of
essential criteria:
Safety. This involves not only the animals being
treated but also the human population and the environment.

Several contraceptive systems have been tested
in deer and are reported in the literature. None of the
developed contraceptives, however, have been
accepted with enthusiasm either because of efficacy
or because of the difficulty in their delivery. The
contraceptive most widely tested is the steroidal
compound melengestrol acetate (MGAB; 17a-hydroxy6-methyl-I 6-methylenepregna-4,6-diene-3,20dione; fig. 1) (Budavari 1989, Bell and Peterle 1975,
Matschke 1980, Plotka and Seal 1989). MGA is
approved by FDA for use in cattle (0.5 mg is orally
administered daily; Zimbelman and Smith [1966]) for
the suppression of estrus, increased rate of weight
gain, improved feed efficiency (Bennett 1993), and,
more recently, estrus synchronization in the United
States. Another steroid tested is levenorgesterel (also
referred to as norgestrel; 13~thyI-17cc-ethynyl-17phydroxygon-4-en-hne; fig. 1) (Budavari 1989, Plotka
and Seal 1989, White et al. 1994). Levenorgesterel is
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than the MGA implants. Unexpectedly, both studies
that used levenorgesterel in deer reported thatadministered at dosages similar to those used efficaciously in humans-levenorgesterel was not an
effective contraceptive in deer (Plotka and Seal 1989,
White et. al. 1994).
Both MGA and levenorgesterel were delivered
via silicone (polydimethylsiloxane) (Roseman 1972).
Because controlled chronic release of steroids in vivo
(which is necessary for steroidal contraception) is
obtained with silicone implants, and because they are
biocompatable in mammals (Dziuk and Cook 1966),
silicone proves to be an efficacious delivery system
suitable for steroidal compounds in deer (Kesler
1989).

Norethindrone Acetate (NA)

Acetate

Figure 1. Chemical structures of melengestrol acetate (top).
levenorgesterel (middle), and norethindrone acetate (bottom)

the active component of the Norplant@ implant approved for human use as a contraceptive implant by
FDA in the United States (McCauley and Geller 1992).
Although effective, MGA requires the implantation of a relatively large implant. These implants
necessitate capturing the target animal and performing
minor surgery for implantation (Plotka and Seal 1989).
The implants have been demonstrated to be efficacious for several breeding seasons (Matschke 1980).
Levenorgesterel also requires animal restraint for
implant placement; however, the implants are smaller

The first compound selected for efficacy evaluation
was norethindrone acetate (19-nor-1 7p-ethynyl178-01-3-one acetate; fig. 1) (Budavari 1989). Its
chemical structure is very similar to that of levenorgesterel. NA is used in combination with ethynylestradiol
in the United States (with FDA approval) as an oral
contraceptive in humans. A human contraceptive was
selected because investigators originally assumed that
it would be reasonable to obtain FDA approval (for use
In deer) for a compound already approved for a
human use. NA was also selected because (1) the
acetate provides longer in vivo half-life (Sinkula 1978),
and (2) esterification enhances steroid secretion from
silicone implants (Christensen and Kesler 1984 and
1986, Kesler et al. 1996). NA implants have been
used efficaciously (as a contraceptive) in humans
(McCauley and Geller 1992). The first, and last, study
(as reported below) was in beef heifers; the compound
norgestomet was then selected for evaluation as a
deer contraceptive.
Fourteen beef heifers were selected for the
study. Heifers were divided into two groups. All
heifers had been previously synchronized with prosta(PGF2=;Kesler 1985a and b, Kesler and
glandin FZm
Favero 1989a) and observed for estrus. Twelve days
after detected estrus, all heifers were bled, and
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plasma was assayed by a validated enzyme-linked
immunosorbent assay (ELISA) (Kesler et al. 1990) for
progesterone concentrations. All 14 heifers had
progesterone concentrations greater than 1.5 ngIrnL,
which suggests that they had corpora lutea that
developed subsequent to the previously detected
estrus (Kesler et al. 1981). Half (7) of the heifers were
subcutaneously implanted with an NA matrix silicone
implant. The cylindrical implants, each 3.5 mm in
diameter and 2.5 cm in length, were implanted
subdermally on the convex surface of the ear. Each
treated heifer received one implant that contained
11.5 mg of NA (equivalent to 8.35 mg of norethindrone). At the time of implant insertion, all heifers
were administered a luteolytic dose of PGF,-. Implants were left in situ for 4 days; after removal, total
remaining NA was determined (Kesler et al. 1995 and
1 9 8 9 ~ ) .In vitro implant secretion over 4 days was
also determined and corrected for in vivo secretion by
the procedure reported by Machado (1994).
NA was released from the silicone implants in a
typical linearly declining fashion (r = -0.997; y =
x (-0.21) + 1.15) (Ferguson et al. 1988, Kesler and
Favero 1989c, Kesler et al. 1995). Over the 4-day
period, a total of 2.53 mg (22 percent of the total) was
delivered in vivo. Three of the four control heifers
(43 percent) were detected in estrus whereas all
seven (100 percent) of the treated heifers were
detected in estrus (table 1).
Estrus was detected at similar times after PGFZm
treatment for both groups. To verify PGF,=-induced
luteolysis, all heifers were bled 2 days after PGF,u
treatment, and plasma was assayed for progesterone
concentrations (Kesler et al. 1990). The progesterone
concentrations in all heifers suggested that luteolysis
was ensuing or had ensued.
In summary, NA did not suppress estrus. In fact,
during a period of high NA secretion (2.53 mg over the
4-day period), there was a tendency for more (P = 0.02)
NA-treated heifers than control heifers to display
estrus. Therefore, NA was not considered further.

Table 1. Norethindrone acetate implant secretion and
estrus supwression efficacy in beef heifers
Item

Control

Number
Number in estrus
Mean interval to estrus

Treated

7

7

3 (43%)

7 (100%);

61 hours

59 hours

0
0

947 Kg
738 ~g
501 kg
341 Kg

-

--

~orethlndroneacetate secreted
Day 1
Day 2
Day 3
Day 4

0
0

Differed from the control group at the 0.02 level of significance

Norgestomet Chemistry and
Physiology
Chemistry
Norgestomet is approved by FDA for use in cattle for
estrus synchronization (Darling 1993). The procedure,
designated Syncro-Mate B8, includes a 9-day implant
containing 6 mg of norgestomet and an intramuscular
injection that consists of 3 mg of norgestomet and
5 mg of estradiol valerate that is administered at the
time of implant insertion (Chien 1978, Kesler et al.
1995). The purpose of the implant is to suppress
estrus. When it is used for estrus synchronization in
cattle, subsequent timed breeding (cattle are bred
48-52 hours after implant removal) pregnancy rates
range from 40 percent to 60 percent (Odde 1990,
Kesler and Favero 1996). Norgestomet has also been
successfully used for resynchronization in cattle
(Favero et al. 1993 and 1995, Machado 1994, Kesler
et al. 1994) and for estrus suppression and synchronization in sheep (Kesler and Favero 1989b and 1997).
Chemically, norgestomet (17a-acetoxy-l l Pmethyl-1 9-norpreg-4-ene-20,dione;
SC 21 009) is a
modified 19-norprogesterone (fig. 2). Norprogesterone
is identical to progesterone except that the methyl
group at the 19 position is absent. Norgestomet has
two other modifications: the presence of a methyl
group at the 11 position and an acetate at the
17 position. Acetate has been added to provide longer
half life in situ (Sinkula 1978). Norgestomet is me-
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(1966), would suggest that MGA is 90 times more
potent than progesterone. This minimal dose of
norgestomet required to suppress estrus in cattle was
confirmed with silicone implant delivery of norgestomet by Machado (1994) and Machado and Kesler
(1996). In their studies, 6-mg and 8-mg silicone
implants were administered to cows for 16 days.
None of the cows with 8-mg implants were detected in
estrus with implants in situ. The smallest daily dose of
norgestomet released by these implants was 136 pg,
which occurred on day 16. However, in three cows
with 6-mg implants, estrus was detected the first day
after implant secretion dropped below 136 pglday.
Although this represents only 16 percent of the treated
cows, 100-percent efficacy of estrus suppression was
lost.

Figure 2. Chemical structures of progesterone (top) and
norgestomet (bottom). Norgestomet is a norprogesterone (exactly
likeprogesterone except the methyl group at the 19 posltion is
absent). Two other differences from progesterone are that
norgestomet has an acetate at the 17 position (in order to increase
half-life in vivo), and a methyl group is included at the 11 position.

tabolized quickly (Moffatt et al. 1993) and is excreted
in the urine and feces (Searle 1982). In both urine
and bile, most of the excreted metabolites are highly
polar materials demonstrated to have only about
4 percent of the progestational activity of norgestomet
in the Clauberg assay (Searle 1982).
Norgestomet is a highly biologically active
progestin. Gilbert et al. (1974) demonstrated that
norgestomet is 15 times more biologically active than
progesterone when orally administered to rabbits and
216 times more biologically active than progesterone
when subcutaneously administered to estradiol-17Ptreated mice. Wishart (1972) demonstrated that
140 pg of norgestomet and 45 mg of progesterone
were required to suppress estrus in all treated heifers
(which means that norgestomet is 321 times more
potent than progesterone in this model). These data,
combined with the data of Zimbelman and Smith

Norgestomet's principal mode of action for estrus
synchronization is by suppressing estrus. Further,
norgestomet has the progesterone biological activity to
maintain pregnancy in ovariectomized heifers (Favero
et al. 1990; Kesler, in press). Favero and coworkers
demonstrated that norgestomet would maintain
pregnancy from day 10 through parturition. Upon
removal of the norgestomet implants, parturition (if the
implants were removed at term) or abortion (if the
implants were removed at midgestation or earlier)
occurred within 52 hours. Therefore, norgestomet is
as effective as progesterone (but at a substantially
reduced dosage) for two of progesterone's main
biological actions: estrus suppression and pregnancy
maintenance.
Progesterone also has a role in regulating
luteinizing hormone (LH) and subsequent follicular
growth and maturation. Experiments utilizing the
commercial hydron (polyethylene glycomethacrylate;
Short 1975) norgestomet implant (6 mg) have demonstrated that, when it was implanted during pro-estrus,
the dominant follicle present was maintained for the
duration of the treatment, and there was no growth of
medium or small follicles (Rajamahendran and Taylor
1991). Systemic estradiol concentrations were also
elevated, and there was insufficient progestin activity
to maintain a strong negative feedback on LH pulse
frequency in a manner comparable to that of the luteal
phase of a normal estrous cycle (Savio et al. 1993).
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Rajamahendran and Taylor (1991) suggested that this
implied that the norgestomet treatment given during
pro-estrus mimics the actions of low concentrations of
progesterone. This time period is, in fact, a time of
low norgestomet secretion by the hydron implant
(Kesler et al. 1995), and, therefore, obtaining a low
progestin effect would be expected. In fact, when
implants were changed during the persistence of the
dominant follicle, LH pulse frequency decreased,
estradiol concentrations decreased, and follicular
atresia occurred (Savio et al. 1993). Therefore, when
given in appropriate amounts, norgestomet was
effective in provoking the progestinlike negative
feedback on LH pulse frequency and on follicular
atresia.

affinity to bovine receptors, it did not bind (less than
0.1-percent cross-reactivity) to highly specific antiprogesterone immunoglobulin G developed in rabbits
(Kesler et al. 1990). Norgestomet exhibits only a
weak ability to competitively bind bovine endometrial
glucocorticoid receptors (Moffatt et al. 1993). Although
norgestomet does not interact with endometrial
estrogen receptors, it exhibits weak estrogenic activity
when tested in an estrogen-dependent stimulation of
human breast cell test. However, to provoke estrogen
stimulation, a dose of at least 100 mg of norgestomet
given at one time would be required (Moffatt et al.
1993).

These conclusions were supported by Butcher et
al. (1992), who reported that daily injections of 100 mg
were was required to elevate systemic progesterone
concentrations to levels of the luteal phase
(5 to 7 ng1mL). In contrast, daily injections of only
45 mg were required to suppress estrus in all treated
animals (Wishart 1972). The dosage selected for the
norgestomet implant was based on the minimal
quantity required to suppress estrus.

To obtain FDA approval for its use in cattle, investigators conducted numerous studies to establish
norgestomet's safety in both the treated animals
(cattle) and humans (Searle 1982). For cattle, studies
were conducted with doses up to 60-fold excess to the
recommended dose (6 mg implants). Daily observation of animals indicated no adverse reactions. Further, postmortem evaluation of the thoracic and
abdominal viscera indicated that norgestomet caused
no adverse effects.

Administration of norgestomet on days 5-21 of
the estrous cycle had no effect on progesterone
secretion by corpora lutea (Domatob et al. 1994) and
no negative effects on the establishment of pregnancy
(Favero et al. 1993 and 1995, Machado 1994, Kesler
et al. 1994). In order to assess the effect of
norgestomet on early corpora lutea function and
development in bovines, norgestomet was administered on days I , 2, 3, and 4 after estrus (2 cowsiday).
The implants were left in situ for 12 days. In all eight
cows, development of the corpora lutea, secretion of
progesterone, and length of the estrous cycle were
unaffected by norgestomet treatment. Therefore,
negative feedback of norgestomet during met-estrus
and di-estrus did not disrupt corpora lutea development or function (Kesler, unpubl. data).
It has been reported that norgestomet has a
higher binding affinity to bovine uterine receptors than
progesterone (Moffatt et al. 1993). Interestingly,
however, although norgestomet has a higher binding

Norgestomet Safety

To evaluate human safety, researchers conducted several studies in both monkeys and rats
(Searle 1982). The study conducted in monkeys was
designed to evaluate the human oral contraceptive
effect of norgestomet. Oral treatment of 30 and
100 pglkg (but not 0 and 10 lgikg) per day increased
the length of menstrual cycles, decreased the ovulation rate, and decreased the number of cycles during
the 84-day treatment period. Throughout the treatment period, the only remarkable effect was amenorrhea, which was observed in five of six and three of
six monkeys orally administered daily doses of 30 or
100 pglkg, respectively. Further, when norgestomet
was administered at these doses, the conception rate
was depressed to zero. The 10 pgikg of norgestomet
per day had no significant effects on menstrual cycle
length, ovulation rate, amenorrhea, or conception rate
(Searle 1982).
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For the rat studies, norgestomet was administered orally by gavage to two generations of rats at
daily doses of 0, 0.0001, 0.001, 0.01,0.1, or 1.0 mgikg
(Searle 1982). Administration of all doses produced
no clinical signs indicative of toxicity. Weight gain was
affected slightly only in the second-generation rats
treated at the 1.0 mglkg daily dosage. Also, in these
same second-generation rats, fertility was slightly
lower when compared to that of controls. There were
no gross or histologic (adrenals, pituitary, and sex
organs) changes that could be attributed to treatment
with norgestomet. Absolute and relative organ
weights from the treated groups were not different
from the controls, although there was a slight decrease
in liver weights in all treated animals.
In published resynchronization studies where
norgestomet was administered during pregnancy, 158
pregnancies have resulted (Favero et al. 1993 and
1995, Machado 1994, Kesler et al. 1994, Domatob et
al. 1997). No adverse effect of any kind has been
observed. Therefore, the administration of norgestomet does not appear to affect embryonic or fetal
development. However, as previously noted,
norgestomet will inhibit parturition and therefore
should not be inadvertently administered to pregnant
animals where the implant is not going to be removed
before parturition (Favero et al. 1990; Kesler, in press).

Contraceptive Efficacy
One study of norgestomet's contraceptive efficacy in
deer was completed in 1995 (Jacobsen et al. 1995),
and another was more recently published (DeNicola et
al. 1997). Jacobsen's study was conducted in confined black-tailed deer. This study included 10 deer of
which 7 were treated with 42-mg norgestomet implants
approximately 1 month before the breeding season.
In addition to the 10 female deer, 2 fertile males were
included in the same confined area. Observations
were collected over a 2-year period after treatment.
Subsequent to treatment, all of the treated
female deer failed to exhibit estrous behavior. Further,
males exhibited neither intentional pursuit, courting,
nor tending bond behaviors toward treated females.
After the first breeding season, all three control deer
fawned, producing two sets of twins and one set of

triplets. None of the seven treated deer fawned. All of
the 10 female deer exhibited estrous behavior the next
breeding season, and all 10 conceived.
Although this study utilized a small sample,
additional studies with white-tailed deer (DeNicola et
al. 1997) confirm the contraceptive effect of the 42-mg
norgestomet implant. In addition, a contraceptive
effect with similar efficacy to that of the 42-mg implant
has been demonstrated with a 21-mg norgestomet
implant (DeNicola et al. 1997).
The desired duration of contraception is controversial. Some groups encourage lifetime sterilization;
others suggest that contraceptives should be reversible. The needle-less norgestomet implant was
designed, as data confirmed, to be a 1-year contraceptive. Therefore, after 1 year of reducing the deer
population, a decision can be made regarding how to
control it in subsequent years.
Release from the 42-mg implant has been
evaluated. This was accomplished by utilizing a
validated in vitro system that mimics in vivo secretion
(Kesler et al. 1995). Implants were evaluated daily
over a 4-month period. The release of norgestomet
from the implants was in a typical linear declining
fashion (see figs. 3 and 4; Kesler et al. 1995). The
best fit line was determined by correlating daily
norgestomet released v. the log of day in vitro. This
produced a correlation coefficient of -0.996. The
maximal release of 638 pg was on the first day.
During the first 3 months, more than 136 pg of
norgestomet was released daily. This is a quantity
that, as described earlier, suppresses estrus in cattle.
The amount of norgestomet released daily thereafter
decreased linearly. Based on the best fit release,
norgestomet was released from the implant for
252 days.
For practical reasons, emphasis was placed on
developing a contraceptive for the female deer.
However, the contraceptive effects of progestins in
males have been known for some time (Liskin and
Quillin 1983). To assess the usefulness of
norgestomet in male animals, researchers conducted
a preliminary study to evaluate its effects on fertilityrelated factors in male rats.
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This study included six males rats that were
12 weeks old at the onset of the experiment. Three
rats served as controls and received no treatment.
The other three rats were each administered one 6-mg
silicone implant. At the end of 9 days, the implants
were removed and replaced with new 6-mg silicone
implants. This cycle continued for 63 days (7 implantslrat-9 dayslimplant). On day 63, all six rats
were killed and trunk blood was collected. The
plasma was analyzed for testosterone concentrations
via a validated ELlSA (Kesler et al. 1990). In addition,
testes were collected and weighed. Mean individual
testis weight of the norgestomet-treated rats was
reduced (P< 0.01) and was only 37 percent of the
control rats' mean testis weight (table 2). Mean
testosterone concentrations in the plasma of
norgestomet-treated rats were only 15 percent of the
control rats'testosterone concentration. Although not

-
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Figure 3. Actual daily in vitro release of norgestomet. Daily
observations were collected; however, only weekly observations
are illustrated.

Table 2. Mean testosterone concentrations and testes
weights of rats treated with norgestomet.
Item

Control

Treated

Number

3

Mean individual
testis weight

2.08 g

0.76 g'

Mean testosterone
concentrations

4.54 ng/mL

0.66 ng/mLZ

-.

.

.~.

-~

3

Offers from the control group at the 0.01 level of significance.

Differs from the control group at the 0.19 level of signifcance.

highly significant (P= 0.19), norgestomet clearly had a
biological effect on testosterone concentrations. A
high level of significance ( P < 0.05) was not achieved
because the untreated rats demonstrated significant
variability in their testosterone concentration and
because so few animals were included in this prelimi-

-
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100200
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Figure 4. Daily release (with days converted to log of days) in vitro
of norgestomet Daily observations were collected; however. only
weekly observations are illustrated. The regression equation IS Y =
X (-265.26) + 637.23 with Y = norgestomet concentration [pg] and
X =log of days (r = 0 . 9 9 6 ; P < 0.01).
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nary study. However, the three norgestomet-treated
rats had the three lowest concentrations of testosterone in their plasma.
Collectively, these data suggest that norgestomet
may have a contraceptive effect in males. However,
these studies were conducted with high concentrations of norgestomet and not in deer. Further investigations evaluating sperm concentrations in the
epididymis of male deer or in their ejaculate are
needed.

Remote Needle-Less Delivery
Delivery of contraceptives to free-roaming animals is
critical to successfully suppressing reproduction. The
idea contraceptive should (1) be capable of being
delivered remotely, (2) not pollute the environment,
and (3) allow control such that only animals intended
to be treated are treated and that the drug is handled
and dispensed properly.
The norgestomet implants used in the deer
efficacy studies were needle-less implants (fig. 5) that
could be delivered at distances up to 40 m from the
target animal (DeNicola et al. 1996). The needle-less
implants have two major components. Their outer
shell is manufactured from food-grade biodegradable
and biocompatable chemicals. The components are
already approved as food additives; even if all of the
implant remained in place at the time of slaughter and
was eaten by humans, that would not pose a hazard
(U.S. Government 1993). The outer biodegradable
shell is 0.635 cm in diameter and 2 cm long. The
second component is the norgestomet manufactured
in a matrix silicone implant. The silicone matrix is
0.42 cm in diameter and 1.4 cm long. It weighs 21 5 mg,
of which 42 mg (19.5 percent) is norgestomet. The
outer shell combined with the siliconelnorgestomet
weighs about 880 mg.
The needle-less implants are propelled via a
compressed-air delivery system. For the 1995 study
(Jacobsen et al. 1995), the needle-less implants were
delivered at 26,152 cmlsecond (858 feetlsecond)
producing 3.07 x l o 5g-cm (22.15 foot-pounds) of

Figure 5. The needle-less norgestomet implant used in the deer
studies. The photo shows the outer biodegradable shell (0.635cm
in dlameter and 2 cm long) and the inner silicone matrix
norgestomet implant (0.42 cm in diameter and 1.4 cm long).

kinetic energy. This system was designed for use in
cattle, whose skin is far thicker than that of deer
(Kesler and Favero 1997). Propelling the implants with
that much kinetic energy caused trauma in deer
(Jacobsen et al. 1995).
Jacobsen's coworkers administered the needleless implants in biceps femoris or semitendinosus or
semimembranosus muscular at a distance of 3-30 m.
Upon contact, deer exhibited one of two reactions:
fleeing response without any apparent change in gait,
followed by standing and grooming of the administration site, or immediate carriage of the hindlimb and
lack of attempted weight bearing for variable durations.
In subsequent studies, the needle-less implant
has been delivered with far less kinetic energy. Using
less kinetic energy does not compromise the accuracy
but significantly reduces the trauma in deer (DeNicola
et al. 1997). In fact, when needle-less implants can
be delivered silently, deer have minimal reaction to
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their delivery. In one study where cortisol concentrations were monitored to evaluate stress caused by the
needle-less implant, they were not increased (Kesler,
unpubl. data).
Upon contact with the skin, the needle-less
implant first causes it to stretch (Gould 1984). After
stretching, the implant penetrates the skin by producing a slit in it. After penetration has occurred, the
skin then contracts back to almost its original form,
with only a small slit left behind. The entry slit is
shorter than the diameter of the projectile. Minimal, if
any, bleeding occurs after penetration. Scab formation follows (Willis et al. 1994, DeNicola et al. 1996).
The projectile does not carry a portion of the animal's
hide into the wound but leaves behind only a small,
raised welt on the skin at the point of projectile entry
(Drake and Paul 1976, Kesler et al. 1989a).

Table 3. In vitro and i n vivo dissolution of the
biodegradable shell of the needle-less norgestomet
implant
Hour

5

98

This remote delivery system is unique and has
many advantages over all other delivery formats.
Another remote delivery system utilizes syringe darts.
Although syringe darts provide remote delivery, a
nondegradable syringe and needle remain in the
environment. Another remote delivery system being
proposed utilizes genetically engineered viruses which
provides no or very minimal control on its spread
(Morell 1993, Wagner et al. 1994).

'98.25

100

'6.39

-

' In vitro condtions conssted of suspending the implant shell in 100 mL of
phosphate buttered salne (pH 7.0) at 37 'C.
I

. .O

,,!,,,I.

nrlr.

Upon entry into living tissue, the outer shell
dissolves in vivo in approximately 6 hours. I conducted both in vitro and in vivo studies to determine
dissolution of the outer shell (table 3). The matrix
silicone implant, although biocompatable and nonirritating, remains and delivers norgestomet by Fick's first
law of diffusion as long as there is norgestomet
contained within the silicone. By design, two deer that
have been remotely treated with needle-less
norgestomet implants were killed (about 2 months
after treatment), and investigators examined the
administration sites and musculature. In both cases,
the norgestomet-silicone implant was recovered.
Surrounding tissue was normal (DeNicola et al. 1996).

Percent of implant dissolved

.

:.

,

..

.,n I 'i,r i :,I <:eo ..l. .~a'lco.,
r1uilrlt '9 "IC
:ant :-r
k 5 ,.<,,'4 .,3:3
?.I.%,
m Q 3 v 2 ' : ? >"Vt ..,CO'S '?., :?:,'?<
271: Z E I - ' ~ ? ? . ~ ~ a m o . r ~irr,.?'%r:
or
.:ranrJ

r

N o observatons were collected lor tmes marked 'At 5 hours after mpantation. approxmately 2 percent. 0 percent, 3 percent.
and 2 percent of the implant was rernanng.
The implant shell had completely dssolved at 6.08, 6 42, and 6.67 hours
after placing the mplants n solution
iAt 24 hours after ~mplantaton,no intact implants were present in any of the
four treated rabbits.

Government Regulations
It is not the purpose of this article to review government regulations; however, it is important to make a
few important comments. First and foremost, the
norgestomet-silicone contraceptive reported herein is
not approved for use by FDA. An Investigational New
Animal Drug (INAD) authorization has to be granted to
conduct the experiments reported. FDA has required
that these studies be conducted only on confined
animals and that they do not escape in such a way
that they could enter the human food chain. Although
approved in cattle, norgestomet is not approved for
widespread use in deer. Before that approval is
possible, a sponsor much accomplish numerous tasks
(table 4) to ensure that the product is efficacious and
safe not only to the treated animals but also to the
humans that may consume treated animals. It is my
opinion that this product can be approved by FDA.
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Table 4. Information required to be submitted to the
FDA's Center for Veterinary Medicine when requesting
approval for the marketing of a new animal drug
product (Center for Veterinary Medicine 1994)
1

ldent~flcatlon

-

2

Table of Contents and Summary
I

Chemiqtrv
..

11

Sc~entlflcrat~onaleand purpose

3. Labeilng
i.
Label identification
ii. Nonprescription labeling
iii. Prescription labeling
iv. Use restrictions
v.
Medicated feed labellng
vi. Draft labeling
4. Components and Composition
i.
Components
ii. Composition
iii. Fermentation of drua substance
5. Manufacturing Methods. Facilities, and Controls
I.
Manufacturer
i.
Personnel
iii. Facilitieslequipment
iv. New drug substance synthesis
v.
Raw material control
vi. Manufacturing instructions
vii. Analytical controls
viii. Lot control number
xi. Container
x.
Stability
xi. Additional procedures
xii. GMP (good manufacturing practice) compliance

-

~

-

6. Samples

7

Analyt~calMethods for Res~dues

8

Ev~denceto establ~shsafety and effectlveness

9

Good Laboratory Practlce Compliance

10

Environmental Assessment

11

Freedom of lnformatlon Summary

12

Confident~al~ty
of Data and lniormatlon In a New An~malDrug
Appllcatlon

However, requirements for distribution have yet to be
accomplished.
Since animals treated with norgestomet would
have their implant in situ during the hunting season, a
legitimate concern is finding the answer to the question, what will happen to the people who consume
such an implant in a treated animal? First, tissue
studies demonstrate that minimal norgestomet residue
exists in all treated cattle tissues except liver and

kidney (Searle 1982). Second, in regard to consumption of an implant, the silicone is exceptionally durable.
When placed in vitro in concentrated hydrochioric acid
over a 3-day period, the polymer is unaffected. Therefore, complete breakdown and absorption of all
remaining norgestomet (like the effect on compressed
pellets) is extremely unlikely (or impossible). Further,
implants incubated in 250 mL of 1 N hydrochloric acid
(at 37 "C), to mimic the acidic conditions of the
stomach, released the same amount of norgestomet
as in plasma in vitro conditions. New implants incubated for 24 hours in plasma and 1 N hydrochioric
acid released 638 pg and 648 pg, respectively (within
1.5 percent of each other). Therefore, consumption of
an implant a few weeks after implantation would
release less than the safe 10 pglkg daily dose previously discussed in monkeys.

Summary
Progesterone, produced by the corpus luteum, suppresses estrus in deer and cattle. Synthetic
progestins (melengestrol acetate and norgestomet)
that suppress estrus in cattle are also effective in deer.
Synthetic progestins that are effective contraceptives
in humans, however, do not suppress estrus and are
not effective contraceptives in deer or cattle. Steroidal
compounds are often viewed negatively because of
the diethyistilbestrol (DES) scenario, even though they
are widely used by humans. DES became implicated
as a carcinogen because large doses (50 mglday) of
DES given to pregnant women caused an increased
incidence of cervical cancer in their daughters (0.14 to
1.4 cases per thousand exposures [Cheeke 19931).
Norgestomet evokes all progesteronelike actions but
at a much reduced dosage. Further, there are no data
available to indicate that this steroid poses a risk. In
addition to the data reported herein, norgestomet has
been used for over a decade in cattle without any
reported problems to either the cattle or to the human
consumption of meat from treated animals. The only
known progestin potent enough to be manufactured in
a remotely delivered needle-less implant and still be
efficacious as a contraceptive is norgestomet. This
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contraceptive system was evaluated by a scientific
committee for use in wild goats (Warren 1992). That
committee gave the needle-less norgestomet the
highest possible ratings for delivery, safety, and
efficacy. All data support their conclusions. In fact,
the committee rated the needle-less norgestomet
implant as the best contraceptive for wild goats
(Warren 1992). Based on all data available, the same
conclusion can be reached for deer. I encourage
further evaluation and support of the development of
this contraceptive for use in deer.
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